Hybrid endoscopic hemithyroidectomy plus targeted radiofrequency ablation for bilateral papillary thyroid cancer
Official title: Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma
Run by Fujian Medical University · NCT07033572 · Data updated 2026-11-12
It will test whether removing the larger tumor with a gas-less axillo-breast endoscopic hemithyroidectomy and treating a small opposite-side tumor with same-session radiofrequency ablation preserves thyroid function and controls cancer in adults with bilateral papillary thyroid carcinoma.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Fujian Medical University Academic / other |
| Locations | 1 site (Fuzhou, Fujian) |
| Status | Recruiting |
| Started | June 1, 2018 |
| Main results expected | June 30, 2026 |
| Study ends | June 30, 2028 |
| Registry record updated | July 3, 2025 |
| Trial ID | NCT07033572 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–65 with a dominant papillary thyroid carcinoma ≤1.5 cm suitable for endoscopic resection and a contralateral nodule ≤7 mm located ≥2 mm from the posterior capsule, with no contralateral radiologic lymph-node metastasis and medically fit for anesthesia.
✕Probably not a fit
Patients with extrathyroidal extension, gross nodal or distant metastasis, prior neck surgery or irradiation, pregnancy, or serious comorbidities are excluded and unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter registry tests a thyroid-function-preserving alternative to routine total thyroidectomy for adults with bilateral papillary thyroid carcinoma. Eligible patients undergo a remote-access gas-less axillo-breast endoscopic hemithyroidectomy with level VI central-neck dissection on the dominant side, followed during the same anesthesia by ultrasound-guided radiofrequency ablation of a contralateral focus ≤7 mm. Outcomes over 24 months include structural-recurrence-free survival, endocrine-function preservation (thyroid hormone independence), safety (recurrent laryngeal nerve injury, hypocalcemia), and quality of life with scheduled ultrasound and serum Tg, calcium, and PTH checks. The registry builds on a pilot cohort of 11 patients that showed no structural recurrence and preserved endocrine function after a median 17-month follow-up.
Why it matters
Potential benefit: If successful, this approach could let selected patients avoid total thyroidectomy and lifelong thyroid hormone replacement while maintaining cancer control.
How similar studies have gone: A single-center pilot cohort of 11 patients (median 17 months follow-up) reported no structural recurrences, no permanent recurrent laryngeal nerve palsy, and preserved endocrine function, but this combined endoscopic-plus-RFA strategy is not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-65 years. * Dominant-side PTC ≤1.5 cm suitable for endoscopic resection. * Contralateral nodule ≤7 mm located ≥2 mm from posterior capsule. * No radiologic lymph-node metastasis on contralateral side. * Written informed consent. Exclusion Criteria: * Extrathyroidal extension, gross nodal or distant metastasis. * Prior neck surgery, prior RFA/ethanol injection, or neck irradiation. * Pregnancy or lactation. * Serious comorbidities precluding anesthesia or follow-up.
Where it's running
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, China Recruiting
Study contacts
- Principal investigator: Bo Wang MD, Principal Investigator — Fujian Medical University Union Hospital
- Study coordinator: Bo Wang Professor, MD
- Email: wangbo@fjmu.edu.cn
- Phone: +13959123550
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
EMDR group program with optional individual EMDR for people with cancer
This project will try EMDR group therapy plus optional individual EMDR to reduce PTSD symptoms and psychological distress in people diagnosed with cancer.
-
Neoadjuvant treatment response in locally advanced thyroid cancer
This study will test whether neoadjuvant therapies can safely shrink locally advanced thyroid cancers and improve surgical outcomes for patients who then undergo thyroidectomy.
-
Dual-channel near-infrared imaging with AI to locate parathyroid glands
This project tests PTFinder, a device that uses near-infrared autofluorescence and AI to make removed thyroid or parathyroid tissue glow so doctors can quickly and accurately identify parathyroid glands in adults having thyroid or parathyroid surgery.
-
Web-based symptom support after radioactive iodine for differentiated thyroid cancer
This will test a four-week web program called RAI Support to help adults treated with radioactive iodine for differentiated thyroid cancer manage symptoms and improve overall quality of life compared with usual online information.
-
New endoscopic surgery technique for thyroid tumors
This study is testing a new way to perform thyroid surgery using a small dual-port technique to see if it is safer and more effective than the traditional open surgery for people with thyroid tumors.
-
Immediate biopsy versus active ultrasound monitoring for suspicious thyroid nodules
This will try immediate biopsy versus careful ultrasound monitoring to see which causes less anxiety and better thyroid-related quality of life for adults with newly found suspicious thyroid nodules (TI‑RADS 4–5) that are 2 cm or smaller.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.